Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of GLPG2222 in adults with cystic fibrosis (F508del homozygous)
2016-004477-40Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of galicaftor in cystic fibrosis (CF) (5 arms), sponsored by Galapagos NV. Primary endpoint: Safety and tolerability. Started Feb 2017; status: completed.
02
Drugs
galicaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2016-004477-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004477-40.